Patents by Inventor Michael Oestergaard
Michael Oestergaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12275940Abstract: The present disclosure provides half duplex compounds comprising a first oligomeric compound and a second, shorter, oligomeric compound, wherein the first oligomeric compound is complementary to a target nucleic acid and the second oligomeric compound is complementary to the first oligomeric compound. In certain embodiments, the compounds disclosed herein are useful for modulating the expression of extra-hepatic target nucleic acids.Type: GrantFiled: June 27, 2023Date of Patent: April 15, 2025Assignee: Ionis Pharmaceuticals, Inc.Inventors: Michael Oestergaard, Punit P. Seth, Frank Rigo, Chrissa A. Dwyer
-
Patent number: 12234447Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.Type: GrantFiled: March 17, 2022Date of Patent: February 25, 2025Assignee: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-Hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
-
Patent number: 12152244Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount, activity, or expression of the target nucleic acid in a cell. In certain embodiments, hybridization results in selective modulation of the amount, activity, or expression of a target Huntingtin gene or Huntingtin transcript in a cell.Type: GrantFiled: January 27, 2022Date of Patent: November 26, 2024Assignee: Ionis Pharmaceuticals, Inc.Inventors: Michael Oestergaard, Punit P. Seth, Eric E. Swayze
-
Publication number: 20240382605Abstract: Provided herein are oligomeric compounds comprising a bicycle ligand and a modified oligonucleotide. This compound may comprise a bicycle ligand as the cell-targeting moiety, and may also comprise a conjugate linker to connect the bicycle ligand and modified oligonucleotide. This compound may be used in conjunction with a pharmaceutically acceptable salt.Type: ApplicationFiled: September 29, 2022Publication date: November 21, 2024Applicants: Ionis Pharmaceuticals, Inc., BicycleTx LimitedInventors: Punit P. Seth, Michael Oestergaard, Michele Carrer, Michael Tanowitz, Michael Rigby, Michael Skynner, Steven Stanway, Liudvikas Urbonas, Katerine Van Rietschoten
-
Publication number: 20240368592Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.Type: ApplicationFiled: December 5, 2023Publication date: November 7, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Eric E. Swayze
-
Publication number: 20240325425Abstract: Provided herein are compounds, pharmaceutical compositions, and methods of use for selectively reducing the amount or activity of HTT RNA comprising SNP rs7685686 in a cell or subject, and in certain instances reducing the amount of mutant HTT protein in a cell or subject. Such compounds, pharmaceutical compositions, and methods of use are useful to ameliorate at least one symptom or hallmark of Huntington's disease.Type: ApplicationFiled: February 16, 2024Publication date: October 3, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Michael Oestergaard, Punit P. Seth
-
Publication number: 20240293563Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.Type: ApplicationFiled: February 23, 2024Publication date: September 5, 2024Inventors: Brett P. MONIA, Thazha P. PRAKASH, Garth A. KINBERGER, Richard LEE, Punit P. SETH, Michael OESTERGAARD, Mehran NIKAN, Shalini ANDERSSON, Eva Carina AMMALA, Daniel Laurent KNERR, Maria OLWEGARD-HALVARSSON, William John DRURY, III, Eric VALEUR
-
Publication number: 20240294923Abstract: The present disclosure provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. In certain embodiments, certain oligomeric compounds selectively reduce the expression of a target nucleic acid transcript relative to a non-target nucleic acid transcript.Type: ApplicationFiled: August 11, 2023Publication date: September 5, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Michael Oestergaard, Punit P. Seth, Eric E. Swayze
-
Publication number: 20240279664Abstract: The present disclosure provides half duplex compounds comprising a first oligomeric compound and a second, shorter, oligomeric compound, wherein the first oligomeric compound is complementary to a target nucleic acid and the second oligomeric compound is complementary to the first oligomeric compound. In certain embodiments, the compounds disclosed herein are useful for modulating the expression of extra-hepatic target nucleic acids.Type: ApplicationFiled: June 27, 2023Publication date: August 22, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Michael Oestergaard, Punit P. Seth, Frank Rigo, Chrissa A. Dwyer
-
Publication number: 20240141343Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.Type: ApplicationFiled: June 12, 2023Publication date: May 2, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Eric E. Swayze
-
Publication number: 20240002851Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.Type: ApplicationFiled: January 25, 2023Publication date: January 4, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Brooke A. Anderson, Xue-Hai Liang, William John Drury, III, Michael Oestergaard, Michael T. Migawa, Punit P. Seth
-
Patent number: 11732261Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.Type: GrantFiled: September 3, 2020Date of Patent: August 22, 2023Assignee: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Eric E. Swayze
-
Patent number: 11725208Abstract: The present disclosure provides half duplex compounds comprising a first oligomeric compound and a second, shorter, oligomeric compound, wherein the first oligomeric compound is complementary to a target nucleic acid and the second oligomeric compound is complementary to the first oligomeric compound. In certain embodiments, the compounds disclosed herein are useful for modulating the expression of extra-hepatic target nucleic acids.Type: GrantFiled: December 14, 2018Date of Patent: August 15, 2023Assignee: Ionis Pharmaceuticals, Inc.Inventors: Michael Oestergaard, Punit P. Seth, Frank Rigo, Chrissa A. Dwyer
-
Patent number: 11629348Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.Type: GrantFiled: February 15, 2022Date of Patent: April 18, 2023Assignee: Ionis Pharmaceuticals, Inc.Inventors: Brooke A. Anderson, Xue-hai Liang, William John Drury, III, Michael Oestergaard, Michael T. Migawa, Punit P. Seth
-
Publication number: 20230113863Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.Type: ApplicationFiled: April 4, 2022Publication date: April 13, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Eric E. Swayze
-
Publication number: 20230068063Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.Type: ApplicationFiled: March 17, 2022Publication date: March 2, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
-
Publication number: 20230002763Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount, activity, or expression of the target nucleic acid in a cell. In certain embodiments, hybridization results in selective modulation of the amount, activity, or expression of a target Huntingtin gene or Huntingtin transcript in a cell.Type: ApplicationFiled: January 27, 2022Publication date: January 5, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Michael Oestergaard, Punit P. Seth, Eric E. Swayze
-
Publication number: 20220186222Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.Type: ApplicationFiled: February 15, 2022Publication date: June 16, 2022Applicant: Ionis Pharmaceuticals, Inc.Inventors: Brooke A. Anderson, Xue-hai Liang, William John Drury, III, Michael Oestergaard, Michael T. Migawa, Punit P. Seth
-
Patent number: 11332733Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.Type: GrantFiled: February 12, 2019Date of Patent: May 17, 2022Assignee: lonis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
-
Patent number: 11236335Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount, activity, or expression of the target nucleic acid in a cell. In certain embodiments, hybridization results in selective modulation of the amount, activity, or expression of a target Huntingtin gene or Huntingtin transcript in a cell.Type: GrantFiled: February 18, 2020Date of Patent: February 1, 2022Assignee: Ionis Pharmaceuticals, Inc.Inventors: Michael Oestergaard, Punit P. Seth, Eric E. Swayze
